Post-marketing Surveillance of Linaclotide Tablet in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation (Excluding Constipation Due to Organic Diseases)

    Not Recruiting
  • End date
    Dec 6, 2021
  • participants needed
  • sponsor
    Astellas Pharma Inc
Updated on 13 June 2021
Medical Affairs Europe
Primary Contact
Site JP00026 (1.4 mi away) Contact
+46 other location


The objective of this study is to evaluate the long-term safety and efficacy of linaclotide in post-marketing use.


This is a post-marketing long-term specified drug use-result survey study required for products in Japan. The investigator will register the patient who have been taking this product for the first time within 14 days after the start of treatment (inclusive of the start day). For each of the registered patients (including withdrawals and dropouts), the investigator will enter the survey data on the case report form.

Condition Irritable Bowel Syndrome With Constipation, Chronic Constipation
Treatment Linaclotide
Clinical Study IdentifierNCT03471728
SponsorAstellas Pharma Inc
Last Modified on13 June 2021

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note